Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2024-10-01

Original market date: See footnote 1

2005-07-19

Lot number: See footnote 2

M1034MR

Expiry date: See footnote 2

2026-11-30

Product name:

TARCEVA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02269015

Product Monograph/Veterinary Labelling:

Date: 2018-09-04 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

HOFFMANN-LA ROCHE LIMITED
7070 Mississauga Road
Mississauga
Ontario
Canada L5N 5M8

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01EB02 ERLOTINIB

Active ingredient group (AIG) number:See footnote5

0151203002

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
ERLOTINIB (ERLOTINIB HYDROCHLORIDE) 100 MG
Version 4.0.3

"Page details"

Date modified: